Elsevier

Biomaterials

Volume 33, Issue 22, August 2012, Pages 5534-5540
Biomaterials

Enzymatic degradation of heparin-modified hydrogels and its effect on bioactivity

https://doi.org/10.1016/j.biomaterials.2012.04.022Get rights and content

Abstract

The extracellular matrix is continually remodelled by the action of various enzymes such as heparanase, which specifically targets heparan sulfate (HS) and is found in human platelets at high levels. The activity of heparin-containing hydrogels following incubation with platelet extract (PE) was investigated in order to simulate the responses that might occur when the hydrogels, as tissue engineered scaffolds, come in contact with blood products at the site of an injury. The heparanase activity of PE on heparin, used as a model of HS, was confirmed by the decrease in molecular weight. PE treatment diminished heparin's anticoagulation property but increased its FGF-2 signalling activity, suggesting that the PE's heparanase activity cleaves at the 3-O-sulfated glucosamine to produce large fragments that can signal cell receptors. The dual effect observed when poly(vinyl alcohol)/heparin co-hydrogels were incubated with PE supports the hypothesis of platelets having the capacity to limit anticoagulation and thus promote blood clot formation, which may be critical in the process of tissue repair.

Introduction

Tissue engineered scaffolds are designed to mimic the extracellular matrix (ECM) by their structure and interactions with the surrounding host environment. Heparan sulfate (HS) molecules, which are a major part of the ECM, are continually synthesised and replaced in the body, a process that helps maintain homeostasis and regulate angiogenesis. HS is synthesised as a part of HS proteoglycan (HSPG), which consists of a protein core that carries linear HS chains composed of alternating hexuronic acid and glucosamine residues. These residues are differentially sulfated to create polydisperse chains with variably charged regions [1]. The HSPG sequesters numerous enzymes, growth factors and cytokines on the cell surface and in the ECM, often acts as an inactive reservoir [2]. Cleavage of the HSPG or HS chains releases fragments of these proteins or polysaccharides from the ECM and can affect their bioactivity [3]. In humans, the protein core of HSPG is susceptible to degradation by several proteases while the HS chains are cleaved by a single heparanase enzyme, an endo-β-glucuronidase that is often referred to as heparanase-1.

Heparanase cleaves HS at specific sites to release HS fragments as well as proteins such as growth factors that are trapped within the ECM or on cell surfaces [4], [5], making them available to the cell surface receptors and causing a change in the environmental conditions that may modulate local tissue responses. One of the primary functions of heparanase is to degrade basement membrane HSPG at sites of injury or inflammation [6], [7], [8], allowing the migration of inflammatory cells and releasing HS-bound growth factors that promote the migration and survival of endothelial cells [9]. The release of basic fibroblast growth factor (FGF-2) by the heparanase action on HS has traditionally been correlated with cell invasion during angiogenesis and inflammation [10].

Platelets have been shown to be a good source of heparanase and the heparanase activity has been reported to be optimum at a pH range of 5.1–6.8 [6], [11], [12], [13]. Other sources of heparanase include endothelial cells (EC) and smooth muscle cells (SMC), although the HS-degrading activity from these cells has been reported to be less that 10% that of platelet extract [13]. Nevertheless, cell lysates from both EC and SMC have been shown to contain factors that can further activate platelet heparanase.

Enzymatic degradation studies of biologically derived hydrogels have been performed to examine substrate availability on the crosslinked biopolymers for enzyme digestion. Collagen, for example, is degraded by metalloproteases and serine proteases, allowing degradation to be locally controlled by cells present in the engineered tissue [14]. Most of the studies have often used bacterial enzymes instead of those from mammalian sources, such as in the degradation studies of hydrogels formulated from chondroitin sulfate (CS) [15] and fibrin [16]. Mammalian heparanase differs from other HS-degrading enzymes such as heparinase and heparitinase from Flavobacterium heparinum, which are eliminases that typically cleave HS into di- or tri-saccharide units [17]. Therefore, to simulate the degradation of heparin in vivo and examine the activity of the resulting heparin fragments, human platelet extract (PE) was used in this study as a source of heparanase.

The aim of this study was to expose heparin-functionalised poly(vinyl alcohol) (PVA) hydrogels to enzymatic degradation, in order to simulate a condition that the co-hydrogels were likely to encounter in vivo. Work has been done to gain a better understanding of the HS-degrading action of heparanase on a molecular level [6], [10], but no reports have explored the effect of platelet heparanase on the activity of heparin-based hydrogels. The heparin-degrading activity of heparanase (PE) was examined by analysing the molecular weight of heparin following incubation with PE, as well as the anticoagulation and FGF-2 signalling properties of the heparin fragments. The degradation capacity of PE on the hydrogel-bound heparin was then examined. Following PE-treatment, extracts from the PVA/heparin co-hydrogels were collected and analysed to assess their molecular weight and the corresponding bioactivities.

Section snippets

Materials

Unless otherwise specified, all materials were from Sigma–Aldrich and used without further purification. Human platelet-rich serum (Australian Red Cross Blood Service) was used as received. Three heparin sodium salt samples, from porcine intestinal mucosa, were used: heparin (grade I-A, 17–19 kDa), low molecular weight (LMW) heparin (4–6 kDa), and Deligoparin™ (2–3 kDa, Opocrin, Italy). Coomassie Plus Reagent (Promega), bovine serum albumin (BSA), casein, monoclonal antibodies, biotinylated

Heparanase activity of the platelet extract

Platelets have been shown to be a reliable source from which heparanase could be obtained [7], [13], [25]. The overall protein concentration of the PE used in this study was determined in the Coomasie Plus assay to be 810 ± 28 μg/mL. To determine the presence of heparanase, an ELISA was performed on the PE using HPA-1 as a probe for heparanase. Antibodies against perlecan (7B5) or serglycin (a-ser) served as negative controls while DPBS was the blank control. The PE and DPBS were probed with

Conclusion

The aim of this study was to investigate the activity of heparin that has been functionalised and polymerised as part of a biosynthetic hybrid biomaterial, and incubated with PE in an attempt to model what might happen when the material is exposed to blood or activated plasma, both of which may be present at sites of injury. The heparanase activity of the PE was shown to be pH dependent and consistent with the action of glucuronidase-type enzymes. The PE was also found to be capable of

Acknowledgements

The authors thank Bill Cheng for help with the preparation of the platelet extract, Litania Lie for additional data on the clotting time and cell assays, and the Australian Research Council Discovery Grant (DP0557863) for project funding. AN wishes to acknowledge support from the UNSW Faculty of Engineering Research Scholarship and the Royal Perth Hospital during the preparation of this manuscript.

References (39)

Cited by (20)

  • An ultrasensitive FRET-based fluorescent low molecular weight heparin nanoprobe for quantifying heparanase activity

    2023, Talanta
    Citation Excerpt :

    Initially, radiolabeled HS chains were employed as the substrate, coupling to solid matrices for gel filtration or ultrafiltration separation. Separating the degraded products from the uncleaved substrates, on the other hand, was complicated and burdensome [15–19]. The radioisotopes were then substituted by chemical fluorophores using a homogeneous time-resolved fluorescence (HTRF) method, which necessitated multi-step reagent additions and lacked a linear correlation between the output signal and substrate degradation [20].

  • Hydrogels based on heparin and its conjugates

    2023, Polysaccharide Hydrogels for Drug Delivery and Regenerative Medicine
  • Depolymerization of heparin by dielectric barrier discharge: Effect of operating modes and anticoagulant potential analysis of low-molecular-weight products

    2018, Chemical Physics Letters
    Citation Excerpt :

    Of note, this observed decrease in anticoagulant activity has also been reported previously in other heparin degradation methods including enzymatic depolymerization by heparinase. This has been theorized to be due to disruption of the original structure by degradation [18]. Although the anticoagulant potency decreased, this heparin degradation procedure is relevant for pharmacological application.

  • Low molecular weight heparin mediating targeting of lymph node metastasis based on nanoliposome and enzyme-substrate interaction

    2015, Carbohydrate Polymers
    Citation Excerpt :

    Glycol-splitting of LMWHEP chain generates flexible joints along the HPA, resulting in close interaction and effective inhibition of the heparanase enzyme (Vlodavsky et al., 2007). And LMWHEP can be degraded by the heparin-degrading activity of HPA, demonstrated by in vitro (Lee, Lee, Bae, & Park, 2010) and in vivo (Nilasaroya, Martens, & Whitelock, 2012) studies. But LMWHEP as a medium used for targeting the tumor metastatic lymph node via the drug delivery system modification and the substrate (LMWHEP)–enzyme (HPA) interaction has not been investigated previously.

View all citing articles on Scopus
1

Tel.: +61 2 9385 3948; fax: +61 2 9663 2108.

View full text